A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3854-3861

  Tolcher, Anthony W ^a   Chi, Kim ^d   Kuhn, John ^b   Gleave, Martin ^d   Patnaik, Amita ^a   Takimoto, Chris ^a   Schwartz, Garry ^c   Thompson, Ian ^b   Berg, Kristin ^a   D'Aloisio, Susan ^d   Murray, Nevin ^d   Frankel, Stanley R ^e   Izbicka, Elzbieta ^a   Rowinsky, Eric ^a  

^a CTRC Institute for Drug Development   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e Genta Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; OBLIMERSEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPOPHOSPHATEMIA; LACRIMATION; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TAXOIDS; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 21044431880     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2145     Document Type: Article

References (33)

1. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
2. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
3. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8.
4. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
5. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-6.
6. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 1993;53:1853-61.
7. Violette S, Poulain L, Dussaulx E, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 2002;98:498-504.
8. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995;55:3902-7.
9. Pratt MA, Krajewski S, Menard M, Krajewska M, Macleod H, Reed JC. Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2. FEBS Lett 1998;440:403-8.
10. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
11. Apakama I, Robinson MC, Walter NM, et al. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996;74:1258-62.
12. McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer [see comments]. J Urol 197;157:569-74.
13. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
14. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000;6:2492-500.
15. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000;86:855-62.
16. Yang D, Ling Y, Almazan M, et al. Tumor regression of human breast carcinomas by the combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs [abstract 4814]. Proc Am Assoc Cancer Res 2002;40:729.
17. Tolcher AW, Roth S, Wynne S, et al. G3139 (Genasense) enhances docetaxel antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograph (PC3) model. Clin Cancer Res 2001;7:3680s.
18. Vrignaud P, Lejeune P, Klem RE, Bissery MC. Combination of G3139 (Genasense™), a Bcl-2 antisense oligonucleotide, with docetaxel (Taxotere®) is active in murine xenograft model of human non-small cell lung cancer [abstract 2865]. Proc Am Assoc Cancer Res 2002;43:578.
19. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000;92:34-41.
20. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001;91:846-50.
21. Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002;8:679-83.
22. Chen H, Hayes DF, Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15:1274-83.
23. Tolcher AW, Kuhn J, Schwartz G, et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139), and antisense oligonucleotide to the Bcl-2 mRNA, and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004;10:5048-57.
24. Tolcher AW, Mooberry SL, Southwell T, Mangold G, Rowinsky EK. Optimal sequence and schedule of oblimersen (G3139) administration when combined with docetaxel in the PC3 human prostate tumor model. Proc Am Assoc Cancer Res 2003;44:629.
25. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrane plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points [see comment]. J Clin Oncol 1996;14:1756-64.
26. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [see comment]. N Engl J Med 2004;351:1502-12.
27. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [see comment]. N Engl J Med 2004;351:1513-20.
28. van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003;17:211-9.
29. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1812-23.
30. Tsujimoto Y, Ikegaki N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 1987;2:3-7.
31. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79-88.
32. Pepper C, Thomas A, Hoy T, Cotter F, Bentley P. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:611-5.
33. Chi KN, Gleave ME, Klasa R, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001;7:3920-7.